Cytokine Gene Polymorphisms in Acute Renal Failure

急性肾衰竭中的细胞因子基因多态性

基本信息

项目摘要

DESCRIPTION (provided by applicant): Acute renal failure (ARF) is a serious complication in hospitalized patients, with an incidence of 5-10%, and mortality exceeding 50% among those who require dialysis. Pro- and anti-inflammatory cytokines play a pivotal role in the host inflammatory responses that mediate the severity of ARF. Yet, the importance of susceptibility genetic factors such as cytokine gene polymorphisms has remained largely unexplored. The principal investigator (PI) has designed a rigorous training program that will provide him with the necessary skills, experience, and opportunities to develop into an independent investigator in the field of inflammatory genetic markers and epidemiology of acute renal failure. He will obtain a Masters of Science in Clinical Care Research, participate in projects utilizing a broad range of study designs for clinical research, and carry out an original research project from its inception to completion. His mentors have extensive experience in clinical and laboratory investigation of ARF and clinical care research in Nephrology. Single nucleotide polymorphisms (SNP) in the promoter region of the human tumor necrosis factor-alpha (TNF-alpha) (position -308), interleukin-6 (IL-6) (position -174) and interleukin-10 (IL-10) (position -1082) genes affect transcriptional activity and have functional relevance. These genetically determined differences might influence variations in host inflammatory responses to stressful stimuli. The hypotheses to be investigated are that SNP involving these cytokines predetermine the severity of ARF, and are independent risk factors for adverse clinical outcomes. The specific aims are to: 1) characterize the frequency of these pro- (TNF-alpha and IL-6) and anti-inflammatory (IL-10) cytokine gene polymorphisms in a cohort of patients with ARF; 2) Examine their relationship to leukocyte production and plasma levels of cytokines as well as clinical and laboratory variables; and 3) Evaluate whether these genetic markers individually or in combinations, predict adverse clinical outcomes, mainly dialysis requirement and mortality. The research project is achievable and promises to provide new insights into the importance of genetic markers as novel susceptibility factors for severity of disease in ARF. The results may help identify target patients who may benefit from anti-cytokine therapies. The PI has assembled a team of scientists to assist in the conduct of the project, and convened and internal and external scientific advisory committee to monitor his progress. The proposed training program and research project will prepare him for a career as an independent investigator.
描述(由申请人提供): 急性肾功能衰竭(ARF)是住院患者的严重并发症,发生率为5-10%,在需要透析的患者中死亡率超过50%。促炎和抗炎细胞因子在介导ARF严重程度的宿主炎症反应中起着关键作用。然而,细胞因子基因多态性等易感遗传因素的重要性在很大程度上仍未被探索。首席研究员(PI)设计了严格的培训计划,将为他提供必要的技能、经验和机会,以发展成为炎症遗传标记和急性肾功能衰竭流行病学领域的独立研究员。他将获得临床护理研究理学硕士学位,参与利用临床研究的广泛研究设计的项目,并从最初到完成进行原创研究项目。他的导师在ARF的临床和实验室研究以及肾脏病的临床护理研究方面拥有丰富的经验。 人肿瘤坏死因子-α(TNF-α)基因启动子区-308位、白介素6(IL-6)-174位和白介素10(IL-10)-1082位基因启动子区域的单核苷酸多态(SNP)影响转录活性,具有功能相关性。这些基因决定的差异可能会影响宿主对应激刺激的炎症反应的差异。有待研究的假设是,涉及这些细胞因子的SNP预先决定了ARF的严重程度,并且是不良临床结果的独立危险因素。其具体目的是:1)确定这些促(肿瘤坏死因子-α和IL-6)和抗炎(IL-10)细胞因子基因多态性在一组ARF患者中的频率;2)检查它们与白细胞产生和血浆细胞因子水平以及临床和实验室变量的关系;以及3)评估这些遗传标记是否单独或联合预测不良的临床结果,主要是透析需求和死亡率。这项研究项目是可以实现的,并有望为遗传标记作为ARF疾病严重程度的新易感因素的重要性提供新的见解。这一结果可能有助于确定可能从抗细胞因子治疗中受益的目标患者。 PI已经组建了一支科学家团队来协助进行该项目,并召集了一个内外科学咨询委员会来监督他的进展。拟议的培训计划和研究项目将为他成为一名独立调查员做好准备。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

BERTRAND L JABER其他文献

BERTRAND L JABER的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('BERTRAND L JABER', 18)}}的其他基金

Comparative Evaluation of Urinary Biological Markers for the Prognostic Stratific
尿液生物标志物预后分层的比较评估
  • 批准号:
    7388341
  • 财政年份:
    2008
  • 资助金额:
    $ 12.53万
  • 项目类别:
Comparative Evaluation of Urinary Biological Markers for the Prognostic Stratific
尿液生物标志物预后分层的比较评估
  • 批准号:
    7585716
  • 财政年份:
    2008
  • 资助金额:
    $ 12.53万
  • 项目类别:
Cytokine Gene Polymorphisms in Acute Renal Failure
急性肾衰竭中的细胞因子基因多态性
  • 批准号:
    6928807
  • 财政年份:
    2003
  • 资助金额:
    $ 12.53万
  • 项目类别:
Cytokine Gene Polymorphisms in Acute Renal Failure
急性肾衰竭中的细胞因子基因多态性
  • 批准号:
    6677662
  • 财政年份:
    2003
  • 资助金额:
    $ 12.53万
  • 项目类别:
Cytokine Gene Polymorphisms in Acute Renal Failure
急性肾衰竭中的细胞因子基因多态性
  • 批准号:
    6946387
  • 财政年份:
    2003
  • 资助金额:
    $ 12.53万
  • 项目类别:
Cytokine Gene Polymorphisms in Acute Renal Failure
急性肾衰竭中的细胞因子基因多态性
  • 批准号:
    7111075
  • 财政年份:
    2003
  • 资助金额:
    $ 12.53万
  • 项目类别:

相似海外基金

FAIRClinical: FAIR-ification of Supplementary Data to Support Clinical Research
FAIRClinical:补充数据的 FAIR 化以支持临床研究
  • 批准号:
    EP/Y036395/1
  • 财政年份:
    2024
  • 资助金额:
    $ 12.53万
  • 项目类别:
    Research Grant
The IDeA State Consortium for a Clinical Research Resource Center: Increasing Clinical Trials in IDeA States through Communication of Opportunities, Effective Marketing, and WorkforceDevelopment
IDeA 州临床研究资源中心联盟:通过机会交流、有效营销和劳动力发展增加 IDeA 州的临床试验
  • 批准号:
    10715568
  • 财政年份:
    2023
  • 资助金额:
    $ 12.53万
  • 项目类别:
Optimizing integration of veterinary clinical research findings with human health systems to improve strategies for early detection and intervention
优化兽医临床研究结果与人类健康系统的整合,以改进早期检测和干预策略
  • 批准号:
    10764456
  • 财政年份:
    2023
  • 资助金额:
    $ 12.53万
  • 项目类别:
The Mayo Clinic NeuroNEXT Clinical Research Site
梅奥诊所 NeuroNEXT 临床研究网站
  • 批准号:
    10743328
  • 财政年份:
    2023
  • 资助金额:
    $ 12.53万
  • 项目类别:
Addressing Underperformance in Clinical Trial Enrollments: Development of a Clinical Trial Toolkit and Expansion of the Clinical Research Footprint
解决临床试验注册表现不佳的问题:开发临床试验工具包并扩大临床研究足迹
  • 批准号:
    10638813
  • 财政年份:
    2023
  • 资助金额:
    $ 12.53万
  • 项目类别:
The Minnesota TMD IMPACT Collaborative: Integrating Basic/Clinical Research Efforts and Training to Improve Clinical Care
明尼苏达州 TMD IMPACT 协作:整合基础/临床研究工作和培训以改善临床护理
  • 批准号:
    10828665
  • 财政年份:
    2023
  • 资助金额:
    $ 12.53万
  • 项目类别:
Improving Multicultural Engagement in Clinical Research through Partnership with Federally Qualified Health Centers and Community Health Worker Programs
通过与联邦合格的健康中心和社区卫生工作者计划合作,改善临床研究中的多元文化参与
  • 批准号:
    10823828
  • 财政年份:
    2023
  • 资助金额:
    $ 12.53万
  • 项目类别:
Promoting a Culture Of Innovation, Mentorship, Diversity and Opportunity in NCI Sponsored Clinical Research: NCI Research Specialist (Clinician Scientist) Award Application of Janice M. Mehnert, M.D.
在 NCI 资助的临床研究中促进创新、指导、多样性和机会文化:Janice M. Mehnert 医学博士的 NCI 研究专家(临床科学家)奖申请
  • 批准号:
    10721095
  • 财政年份:
    2023
  • 资助金额:
    $ 12.53万
  • 项目类别:
Clinical Research Center for REstoration of NEural-based Function in the Real World (RENEW)
现实世界神经功能恢复临床研究中心 (RENEW)
  • 批准号:
    10795328
  • 财政年份:
    2023
  • 资助金额:
    $ 12.53万
  • 项目类别:
Clinical Research and Academic Success in Obstetrics & Gynecology
产科临床研究和学术成就
  • 批准号:
    10828252
  • 财政年份:
    2023
  • 资助金额:
    $ 12.53万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了